Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Executive Summary
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.
You may also be interested in...
BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients
GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.
BIO Notebook: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients
GSK, BridgeBio, and the US FDA’s patient-focused drug development director discuss contingency planning as the BIO International Convention concludes in Boston.
Is The US Less Attractive Than India? A Proxy Comparison Via Strides And Torrent
Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics